Table 2

OAC exposure among incident cases of IS in the UK and Denmark

Incident cases of IS
UK (IMRD-UK)
N=615
n (%)
Denmark (RSD)
N=643
n (%)
Any OAC
 Current use267 (43.4)339 (52.7)
 Intermediate use29 (4.7)22 (3.4)
 Discontinued137 (22.3)131 (20.4)
 Non-use176 (28.6)142 (22.1)
Any VKA
 Current use141 (22.9)164 (25.5)
 Intermediate use16 (2.6)5 (0.8)
 Discontinued84 (13.7)75 (11.7)
 Non-use*368 (59.8)390 (60.7)
Any NOAC
 Current use126 (20.5)175 (27.2)
 Intermediate use13 (2.6)17 (2.6)
 Discontinued53 (13.7)56 (8.7)
 Non-use*383 (62.3)386 (60.0)
  • Definitions of OAC exposure were as follows: current use, when the prescription supply lasted until the index date or ended within the 7 days before the index date; intermediate use, when the prescription supply ended 8–30 days before the index date; discontinued, when the prescription supply ended ≥31 days before index date; non-use, when there was no prescription before the index date.

  • *Non-users of any VKA and non-users of any NOAC were not mutually exclusive categories.

  • †In the UK, six cases were current users of both a VKA and a NOAC and were not included. These six cases were considered ‘OAC switchers’ and not current users of one OAC class. In Denmark, 9 cases were considered ‘OAC switchers’ and not current users of one OAC class.

  • IMRD-UK, IQVIA Medical Research Data-UK; IS, ischaemic stroke; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; RSD, Region of Southern Denmark; VKA, vitamin K antagonist.